Jan 29, 2018 • 4:05 pm EST Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
Dec 22, 2017 • 7:05 am EST Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
Dec 14, 2017 • 7:35 am EST Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
Nov 27, 2017 • 4:05 pm EST Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering
Nov 27, 2017 • 7:30 am EST Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Nov 15, 2017 • 8:00 am EST Corbus Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Nov 8, 2017 • 8:05 am EST Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements
Nov 6, 2017 • 8:30 am EST Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study
Oct 31, 2017 • 7:05 am EDT Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases